Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21

Benzinga · 5d ago
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $19 to $21.